Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
The significance of HIV 'blips' in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)

Kanapathipillai R, McManus H, Kamarulzaman A, Lim PL, Templeton DJ, Law M, Woolley I.

(2014), PLoS One, 9(2), e86122

Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy

Haskelberg H, Mallon PW, Hoy J, Amin J, Moore C, Phanuphak P, Ferret S, Belloso WH, Boyd MA, Cooper DA, Emery S

(2014), J Acquir Immune Defic Syndr, 67(2), 161-8

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel

(2014), JAMA, 312(4), 410-25

Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study

Dawood FZ, Roediger MP, Grandits G, Miller D, Fisher M, Zhang ZM, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ; INSIGHT SMART Study Group

(2014), J Electrocardiol, 47(2), 264-71

Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks

Bloch M, Tong WW, Hoy J, Baker D, Lee FJ, Richardson R, Carr A; TROP (Switch from Tenofovir to Raltegravir for Low Bone Density) study team

(2014), HIV Med, 15(6), 373-80

CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals

Bastidas S, Graw F, Smith MZ, Kuster H, Günthard HF, Oxenius A

(2014), J Immunol, 192(4), 1732-44

What has the Young Physician Leaders Programme achieved?

Giles ML, Vincent FB, Volkenstein S, Shefin SM, Silva A, Fredrick F; Young Physician Leadership Group 2013

(2014), Lancet, 384(9937), 26-7

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

Seymour JF, Pfreundschuh M, Trnĕný M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators

(2014), Haematologica, 99(8), 1343-9

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi

(2014), Haematologica, 99(2), 292-8

Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period

Macesic N, Morrissey CO, Cheng AC, Spencer A, Peleg AY

(2014), Transpl Infect Dis, 16(6), 887-96

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF

(2014), Br J Cancer, 111(6), 1072-9

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP

(2014), N Engl J Med, 371(10), 906-17

Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014

Morrissey CO, Gilroy NM, Macesic N, Walker P, Ananda-Rajah M, May M, Heath CH, Grigg A, Bardy PG, Kwan J, Kirsa SW, Slavin M, Gottlieb T, Chen S

(2014), Intern Med J, 44(12b), 1298-314

The dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in mice

Lancaster GI, Kraakman MJ, Kammoun HL, Langley KG, Estevez E, Banerjee A, Grumont RJ, Febbraio MA, Gerondakis S

(2014), PLoS One, 9(11), e111524

Lethal giant larvae 1 tumour suppressor activity is not conserved in models of mammalian T and B cell leukaemia

Hawkins ED, Oliaro J, Ramsbottom KM, Ting SB, Sacirbegovic F, Harvey M, Kinwell T, Ghysdael J, Johnstone RW, Humbert PO, Russell SM

(2014), PLoS One, 9(1), e87376

c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells

Neo WH, Lim JF, Grumont R, Gerondakis S, Su IH

(2014), J Biol Chem, 289(46), 31693-707

Author reply

Wei A, Fleming S

(2014), Intern Med J, 44(8), 825

Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets

Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE

(2014), Circ Res, 114(7), 1083-93

The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia

Tremblay CS, Curtis DJ

(2014), Curr Opin Hematol, 21(4), 320-5

New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis

Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C

(2014), Intern Med J, 44(6), 525-36

437 438 439 440 441